• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症中的 DNA 修复缺陷与治疗机会。

DNA repair defects in cancer and therapeutic opportunities.

机构信息

Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, Massachusetts 02129, USA.

Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.

出版信息

Genes Dev. 2022 Mar 1;36(5-6):278-293. doi: 10.1101/gad.349431.122.

DOI:10.1101/gad.349431.122
PMID:35318271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8973847/
Abstract

DNA repair and DNA damage signaling pathways are critical for the maintenance of genomic stability. Defects of DNA repair and damage signaling contribute to tumorigenesis, but also render cancer cells vulnerable to DNA damage and reliant on remaining repair and signaling activities. Here, we review the major classes of DNA repair and damage signaling defects in cancer, the genomic instability that they give rise to, and therapeutic strategies to exploit the resulting vulnerabilities. Furthermore, we discuss the impacts of DNA repair defects on both targeted therapy and immunotherapy, and highlight emerging principles for targeting DNA repair defects in cancer therapy.

摘要

DNA 修复和 DNA 损伤信号通路对于维持基因组稳定性至关重要。DNA 修复和损伤信号的缺陷会导致肿瘤发生,但也使癌细胞易受 DNA 损伤的影响,并依赖于剩余的修复和信号活性。在这里,我们回顾了癌症中主要的 DNA 修复和损伤信号缺陷类型、它们引起的基因组不稳定性,以及利用这些缺陷产生的脆弱性的治疗策略。此外,我们还讨论了 DNA 修复缺陷对靶向治疗和免疫治疗的影响,并强调了针对癌症治疗中 DNA 修复缺陷的新原则。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/8973847/173daf2a0315/278f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/8973847/a5eece6cf81e/278f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/8973847/5e7abbc6126d/278f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/8973847/16f16b941e93/278f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/8973847/173daf2a0315/278f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/8973847/a5eece6cf81e/278f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/8973847/5e7abbc6126d/278f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/8973847/16f16b941e93/278f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6891/8973847/173daf2a0315/278f04.jpg

相似文献

1
DNA repair defects in cancer and therapeutic opportunities.癌症中的 DNA 修复缺陷与治疗机会。
Genes Dev. 2022 Mar 1;36(5-6):278-293. doi: 10.1101/gad.349431.122.
2
DNA damage response and prostate cancer: defects, regulation and therapeutic implications.DNA损伤反应与前列腺癌:缺陷、调控及治疗意义
Oncogene. 2015 May 28;34(22):2815-22. doi: 10.1038/onc.2014.238. Epub 2014 Aug 18.
3
Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition.人类癌症中的基因组不稳定性:分子见解以及通过饮食和营养进行治疗性攻击和预防的机会。
Semin Cancer Biol. 2015 Dec;35 Suppl(Suppl):S5-S24. doi: 10.1016/j.semcancer.2015.03.005. Epub 2015 Apr 11.
4
DNA damage repair in breast cancer and its therapeutic implications.乳腺癌中的DNA损伤修复及其治疗意义。
Pathology. 2017 Feb;49(2):156-165. doi: 10.1016/j.pathol.2016.11.002. Epub 2016 Dec 26.
5
DNA repair defects and implications for immunotherapy.DNA 修复缺陷及其对免疫治疗的影响。
J Clin Invest. 2018 Oct 1;128(10):4236-4242. doi: 10.1172/JCI122010.
6
Harnessing DNA Replication Stress for Novel Cancer Therapy.利用 DNA 复制应激进行新型癌症治疗。
Genes (Basel). 2020 Aug 25;11(9):990. doi: 10.3390/genes11090990.
7
The DNA damage response pathway in normal hematopoiesis and malignancies.正常造血与恶性肿瘤中的DNA损伤反应通路
Int J Hematol. 2017 Sep;106(3):328-334. doi: 10.1007/s12185-017-2300-7. Epub 2017 Jul 13.
8
Strategies for targeting the DNA damage response for cancer therapeutics.针对癌症治疗的DNA损伤反应的靶向策略。
Chin J Cancer. 2012 Aug;31(8):359-63. doi: 10.5732/cjc.012.10087. Epub 2012 Jun 14.
9
Genome instability and DNA damage accumulation in gene-targeted mice.基因靶向小鼠中的基因组不稳定性和DNA损伤积累
Neuroscience. 2007 Apr 14;145(4):1309-17. doi: 10.1016/j.neuroscience.2006.10.059. Epub 2007 Jan 9.
10
Noncoding RNAs in DNA Damage Response: Opportunities for Cancer Therapeutics.DNA损伤反应中的非编码RNA:癌症治疗的机遇
Methods Mol Biol. 2018;1699:3-21. doi: 10.1007/978-1-4939-7435-1_1.

引用本文的文献

1
Expressed mutated genes in Sezary syndrome and their potential prognostic value in patients treated with extracorporeal photopheresis.蕈样肉芽肿综合征中表达的突变基因及其在接受体外光化学疗法治疗的患者中的潜在预后价值。
Front Immunol. 2025 Aug 22;16:1589467. doi: 10.3389/fimmu.2025.1589467. eCollection 2025.
2
The SPINK Protein Family in Cancer: Emerging Roles in Tumor Progression, Therapeutic Resistance, and Precision Oncology.癌症中的丝氨酸蛋白酶抑制剂Kazal型相关肽(SPINK)蛋白家族:在肿瘤进展、治疗抗性和精准肿瘤学中的新作用
Pharmaceuticals (Basel). 2025 Aug 13;18(8):1194. doi: 10.3390/ph18081194.
3
Automated machine learning profiling with MAP-HR for quantifying homologous recombination foci in patient samples.

本文引用的文献

1
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.CCNE1 扩增与 PKMYT1 激酶抑制协同致死。
Nature. 2022 Apr;604(7907):749-756. doi: 10.1038/s41586-022-04638-9. Epub 2022 Apr 20.
2
Signatures of TOP1 transcription-associated mutagenesis in cancer and germline.癌症和种系中 TOP1 转录相关诱变的特征。
Nature. 2022 Feb;602(7898):623-631. doi: 10.1038/s41586-022-04403-y. Epub 2022 Feb 9.
3
The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer.
使用MAP-HR进行自动机器学习分析,以量化患者样本中的同源重组灶。
NAR Cancer. 2025 Aug 11;7(3):zcaf025. doi: 10.1093/narcan/zcaf025. eCollection 2025 Sep.
4
Network toxicology reveals collaborative mechanism of 4NQO and ethanol in esophageal squamous cell carcinogenesis.网络毒理学揭示4-硝基喹啉-1-氧化物(4NQO)与乙醇在食管鳞状细胞癌发生中的协同作用机制。
Biochem Biophys Rep. 2025 Aug 2;43:102187. doi: 10.1016/j.bbrep.2025.102187. eCollection 2025 Sep.
5
ALDH18A1 has carcinogenic functions and regulates alternative splicing events of DNA repair-related genes in esophageal carcinoma cells.醛脱氢酶18A1具有致癌功能,并调节食管癌细胞中DNA修复相关基因的可变剪接事件。
Sci Rep. 2025 Aug 7;15(1):28845. doi: 10.1038/s41598-025-08006-1.
6
Bridging technology and medicine: artificial intelligence in targeted anticancer drug delivery.连接技术与医学:人工智能在靶向抗癌药物递送中的应用
RSC Adv. 2025 Aug 4;15(34):27795-27815. doi: 10.1039/d5ra03747f. eCollection 2025 Aug 1.
7
Research progress on the role of the NEIL family in cancer.NEIL家族在癌症中作用的研究进展
Front Cell Dev Biol. 2025 Jul 21;13:1612329. doi: 10.3389/fcell.2025.1612329. eCollection 2025.
8
The prognostic and predictive value of homologous recombination deficiency in gastrointestinal cancer.同源重组缺陷在胃肠道癌中的预后及预测价值
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf141.
9
Deciphering the multifaceted role of in female-related cancers: implications for prognosis and therapeutic responsiveness.解读[具体物质或因素未给出]在女性相关癌症中的多方面作用:对预后和治疗反应性的影响。
Front Immunol. 2025 May 12;16:1591505. doi: 10.3389/fimmu.2025.1591505. eCollection 2025.
10
Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA Damage.在DNA损伤背景下通过靶向ATR/Chk1和ATM/Chk2轴发现癌症脆弱性
Cells. 2025 May 20;14(10):748. doi: 10.3390/cells14100748.
CIP2A-TOPBP1 轴确保染色体稳定性,是 BRCA 突变型癌症的合成致死靶点。
Nat Cancer. 2021 Dec;2(12):1357-1371. doi: 10.1038/s43018-021-00266-w. Epub 2021 Nov 11.
4
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors.RP-3500:一种新型、强效、选择性的ATR 抑制剂,在临床前模型中作为单一疗法和与 PARP 抑制剂联合使用均具有疗效。
Mol Cancer Ther. 2022 Feb;21(2):245-256. doi: 10.1158/1535-7163.MCT-21-0615. Epub 2021 Dec 15.
5
BRCA2 associates with MCM10 to suppress PRIMPOL-mediated repriming and single-stranded gap formation after DNA damage.BRCA2 与 MCM10 结合以抑制 DNA 损伤后 PRIMPOL 介导的重新引发和单链缺口形成。
Nat Commun. 2021 Oct 13;12(1):5966. doi: 10.1038/s41467-021-26227-6.
6
Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells.在人类细胞中,时间上不同的复制后修复机制填补了 PRIMPOL 依赖性单链 DNA 缺口。
Mol Cell. 2021 Oct 7;81(19):4026-4040.e8. doi: 10.1016/j.molcel.2021.09.013.
7
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.组合 ATR 和 PARP 抑制剂(CAPRI):在铂类耐药的复发性上皮性卵巢癌患者中应用塞拉替尼联合奥拉帕利的 2 期研究。
Gynecol Oncol. 2021 Nov;163(2):246-253. doi: 10.1016/j.ygyno.2021.08.024. Epub 2021 Oct 5.
8
Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity.JNJ-64619178 的发现及药理学特性:一种新型的 PRMT5 小分子抑制剂,具有强大的抗肿瘤活性。
Mol Cancer Ther. 2021 Dec;20(12):2317-2328. doi: 10.1158/1535-7163.MCT-21-0367. Epub 2021 Sep 28.
9
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}--methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs.发现 5-{4-[(7-乙基-6-氧代-5,6-二氢-1,5-萘啶-3-基)甲基]哌嗪-1-基}-2-甲基吡啶-3-羧酰胺(AZD5305):一种对 PARP1 具有高选择性的 PARP1-DNA 捕获剂,对 PARP2 和其他 PARPs 的选择性较高。
J Med Chem. 2021 Oct 14;64(19):14498-14512. doi: 10.1021/acs.jmedchem.1c01012. Epub 2021 Sep 27.
10
Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.核 DNA 连接酶 III 的缺失通过暴露单链 DNA 缺口使 BRCA1/53BP1 双缺陷细胞对 PARP 抑制剂耐药性逆转。
Mol Cell. 2021 Nov 18;81(22):4692-4708.e9. doi: 10.1016/j.molcel.2021.09.005. Epub 2021 Sep 22.